AXSM - Axsome Market Cap to Sales Volume
The EV/Revenue multiple visualizes the market valuation of sales, where 8.80 shows the current value of the metric. The Axsome Therapeutics (AXSM) model is scalable: the launch of unique drugs ensures global distribution with high margins. The strategy is based on the repurposing of molecules for CNS treatment, creating pricing power. Axsome Therapeutics (AXSM) is currently expanding its presence in the migraine and depression segments, increasing patient flow.
Analytical breakdowns for Axsome Therapeutics Inc (AXSM)
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Axsome Therapeutics|AXSM - Long-Term Debt to Capital|Short-Term Debt to Capital Axsome Corp|AXSM - Company Debts|Debts to Book Capitalization Ratio Axsome Therapeutics Inc|AXSM - Company Long-Term Debts|Short-Term Debt Axsome Therapeutics|Quick Ratio axsome.com
- earnings and valuation multiples information:
AXSM - Net Income|Future Net Profit Axsome Therapeutics|AXSM - P/E Multiple|Market Cap to Projected Earnings Axsome|AXSM - PEG Multiple|Enterprise Value to EBITDA Ratio Axsome Therapeutics Inc|AXSM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Axsome Therapeutics|AXSM - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth axsome.com|AXSM - Net earnings per share growth this year|Projected earnings per share growth rate for next year Axsome Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:axsome.com - AXSM
Reliable distribution of neurological drugs through specialized climate-controlled channels ensures steady revenue growth for Axsome Therapeutics (AXSM). The current P/S valuation, reflecting the ratio of market capitalization to annual sales volume, allows for a comparison of business value against actual cash flows, helping investors determine the extent of asset overvaluation and balance potential returns against the risks of a late entry.
Competing companies
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Cap to Sales Volume RGC (Regencell Bioscience Ltd)|ACADIA Pharmaceuticals Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio XENE (Xenon Corp)|VKTX: P/S Multiple|Price to Sales supernus.com (SUPN)|Price-to-Revenue Ratio Catalyst Pharmaceuticals, Inc.|DNLI: Market Capitalization-to-Revenue Ratio|P/S Multiple HRMY|P/S Multiple Biohaven Corp (BHVN)|Price-to-Revenue Ratio Amylyx Pharmaceuticals AMLX|TRVI (trevitherapeutics.com) - Price-to-Sales Ratio|Praxis Precision Medicines, Inc. - P/S Multiple|Price to Sales Anavex|CBLL (CeriBell Corp) - Market Cap to Revenue|Prothena Corp (PRTA) - P/S Multiple|Market Cap to Revenue ALEC|ANNX (annexonbio.com) - Market Cap to Sales Volume|P/S Multiple OMER|Price-to-Revenue Coefficient Neurogene Inc|P/S Multiple ACIU (AC Immune Corp)|VYGR - Market Cap to Revenue|NMRA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient scilexholding.com SCLX|TVGN: P/S Multiple|Alpha Cognition Inc. (ACOG) - P/S Multiple|Market Cap to Revenue CGTX|Market Cap to Revenue Ratio IKT (Inhibikase Pharma)|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|Price-to-Revenue Coefficient assertiotx.com|Price-to-Revenue Ratio Coya Therapeutics COYA|VTGN - Market Cap to Revenue|OVID - Price-to-Revenue Ratio|ABOS (Acumen Pharmaceuticals, Inc) - Market Cap to Revenue Ratio|CRVO: P/S Multiple|Price to Sales Alterity Therapeutics Limited (ATHE)|Market Cap to Revenue CLNN|P/S Multiple PepGen Corp|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Price to Sales|Firefly Neuroscience - P/S Multiple|KLTO - P/S Multiple|NRSN (neurosense-tx.com) - Market Cap to Revenue|Market Cap to Revenue Ratio RVPH|Price-to-Revenue Ratio MetaVia Inc.|neuraxis.com (NRXS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG - Price to Sales|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV - Market Cap to Revenue|Athira Pharma, Inc. - P/S Multiple|Price to Sales addextherapeutics.com|ALZN (alzamend.com) - Market Cap to Revenue|Cyclerion Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA (Pasithea) - Market Cap to Sales Volume|P/S Multiple CRGT|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Price to Sales|CHRO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|ITCI: P/S Multiple|longboardpharma.com (LBPH) - P/S Multiple|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Price-to-Sales Ratio|P/S Multiple NRBO|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|P/S Multiple trevena.com TRVN|VIGL: Market Cap to Revenue|anewmeds.com - Market Cap to Sales Volume|CERE: P/S Multiple
